Nervous System News and Research

Latest Nervous System News and Research

Sleep apnea may contribute to fatigue in people with multiple sclerosis

People with multiple sclerosis (MS) might assume that the fatigue they often feel just comes with the territory of their chronic neurological condition.

17 Feb 2014

Scientists develop new paradigms for understanding how human brain works in health, disease

Understanding the human brain is one of the greatest challenges facing 21st century science. If we can rise to this challenge, we will gain profound insights into what makes us human, develop new treatments for brain diseases, and build revolutionary new computing technologies that will have far reaching effects, not only in neuroscience.

17 Feb 2014

Vitamin C may reduce risk of most common type of hemorrhagic stroke, says study

Eating foods that contain vitamin C may reduce your risk of the most common type of hemorrhagic stroke, according to a study released today that will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Scientists discover novel antibody-based therapy that targets progression of kidney fibrosis

Scientists from the University of Sheffield have developed a novel antibody-based therapy which targets the progression of life threating kidney fibrosis.

16 Feb 2014

Brain's ability to rebuild itself after stroke holds promise for treating long-term disability in adults

Enhancing the brain's inherent ability to rebuild itself after a stroke with molecular components of stem cells holds enormous promise for treating the leading cause of long-term disability in adults.

14 Feb 2014

Albert Einstein College professor receives AAAS 2013 Newcomb Cleveland Prize

A study describing the complete wiring diagram for the part of the nervous system that controls mating behavior in male roundworms was chosen as the most outstanding paper published in Science in the year June 2012 to May 2013.

13 Feb 2014

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

UMass Medical School (UMMS) recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).

13 Feb 2014

Cedars-Sinai receives $1M grant to study molecular changes in brain due to air pollutants

Researchers at the Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery at Cedars-Sinai will conduct a study to determine if several potentially toxic compounds that exist in polluted air are capable of entering the brain from the bloodstream and causing brain cancer.

12 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Transcendental meditation technique shows significant reduction in PTSD in just 10 days

African civilians in war-torn countries have experienced the threat of violence or death, and many have witnessed the abuse, torture, rape and even murder of loved ones. Many Congolese living in Ugandan refugee camps are suffering from severe posttraumatic stress disorder (PTSD).

11 Feb 2014

Long-distance signaling molecules tell brain to produce anti-viral interferon

The brain contains a defense system that prevents at least two unrelated viruses-and possibly many more-from invading the brain at large. The research is published online ahead of print in the Journal of Virology.

11 Feb 2014

Researchers shed new light on pain associated with bacterial infections

Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.

11 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

Scientists find a clue as to why muscles weaken with age

Scientists from the School of Medicine at The University of Texas Health Science Center at San Antonio have found a clue as to why muscles weaken with age. In a study published Feb. 5 in The Journal of Neuroscience, they report the first evidence that "set points" in the nervous system are not inalterably determined during development but instead can be reset with age. They observed a change in set point that resulted in significantly diminished motor function in aging fruit flies.

9 Feb 2014

BGSU's Olivucci leverages OSC systems to study retina's melanopsin pigment

Researchers have found that the melanopsin pigment in the eye is potentially more sensitive to light than its more famous counterpart, rhodopsin, the pigment that allows for night vision.

9 Feb 2014

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, according to an animal study appearing February 12 in The Journal of Neuroscience. The findings suggest exercise may be able to slow the progression of retinal degenerative diseases.

9 Feb 2014

Nervous System News and Research

Latest Nervous System News and Research

Sleep apnea may contribute to fatigue in people with multiple sclerosis

Scientists develop new paradigms for understanding how human brain works in health, disease

Vitamin C may reduce risk of most common type of hemorrhagic stroke, says study

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Scientists discover novel antibody-based therapy that targets progression of kidney fibrosis

Brain's ability to rebuild itself after stroke holds promise for treating long-term disability in adults

Albert Einstein College professor receives AAAS 2013 Newcomb Cleveland Prize

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

Cedars-Sinai receives $1M grant to study molecular changes in brain due to air pollutants

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

Omeros announces additional positive data from OMS824 Phase 1 program

Transcendental meditation technique shows significant reduction in PTSD in just 10 days

Long-distance signaling molecules tell brain to produce anti-viral interferon

Researchers shed new light on pain associated with bacterial infections

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

Scientists find a clue as to why muscles weaken with age

BGSU's Olivucci leverages OSC systems to study retina's melanopsin pigment

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in